Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Table 2 Renal composite event rates in EMPA-REG OUTCOME [35], CANVAS program [51], DECLARE-TIMI 58 [36], VERTIS CV [32], CREDENCE [33], and DAPA-CKD [34]

	Treatment arm	Cardiovascular outcomes trials					Renal outcomes trial
	Treatment arm	EMPA-REG OUTCOME	CANVAS program	DECLARE-TIMI 58	Meta-analysis (fixed-effects model)^a	VERTIS CV	CREDENCE	DAPA-CKD^b
Renal composite (Event rate per 1000 patient-years)	Placebo	11.5	9.0	7.0	Events (n/N): 766/34,322	12	40.4	NR
Renal composite (Event rate per 1000 patient-years)	SGLT2i	6.3	5.5	3.7	Events (n/N): 766/34,322	9	27.0	NR
Hazard ratio (95% CI)		0.54 (0.40, 0.75)	0.60 (0.47, 0.77)	0.53 (0.43, 0.66)	0.55 (0.48, 0.64)	0.81 (0.63, 1.04)	0.66 0.53, 0.81)	0.64 (0.52, 0.79)
Renal composite (3-year NNT)		66	97	103	–	–	28	NR

CI confidence interval, NNT number needed to treat, SGLT2i sodium–glucose cotransporter 2 inhibitor
^aMeta-analysis does not include VERTIS CV [44]
^bOutcomes for the T2D subgroup analysis. Renal composite was defined as worsening of renal function, end-stage renal disease, or renal death

ISSN: 1475-2840